Next Article in Journal
An Experience of Donor Lymphocyte Infusion after Reduced-Intensity Conditioning Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Granulomatous Disease
Previous Article in Journal
Mental Rotation in American Children: Diminished Returns of Parental Education in Black Families
Case Report

Pediatric Inflammatory Multisystem Syndrome Temporally Associated with SARS-CoV-2 Treated with Tocilizumab

1
Pediatric Intensive Care Unit, Hospital Roberto del Río, Santiago 13108, Chile
2
Pediatric Intensive Care Unit, Clínica Indisa, Santiago 7500000, Chile
3
Department of Pediatric Immunology and Rheumatology, Hospital Roberto del Río, Santiago 13108, Chile
4
Department of Urology, Clínica Alemana, Santiago 13132, Chile
5
Clínica Alemana, Universidad del Desarrollo, Santiago 13132, Chile
6
Department of Pediatric Infectiology, Hospital Roberto del Río, Santiago 13108, Chile
7
Virology Program, Institute of Biomedical Sciences, School of Medicine, Universidad de Chile, Santiago 13108, Chile
*
Author to whom correspondence should be addressed.
Pediatr. Rep. 2020, 12(3), 142-148; https://doi.org/10.3390/pediatric12030029
Received: 20 October 2020 / Revised: 25 November 2020 / Accepted: 25 November 2020 / Published: 4 December 2020
We describe a case of Pediatric Inflammatory Multisystem Syndrome temporally associated with SARS-CoV-2 (PIMS-TS) in an 8-year-old child. The patient developed multiorgan dysfunction, including mixed shock, cardiac dysfunction with myocarditis, pneumonia, acute kidney failure, and gastrointestinal involvement characterized by inflammation of the wall of the bowel and pancreatitis. After treatment with Tocilizumab and corticoid therapy, he presented clinical improvement and normalization of inflammatory markers. PIMS-TS is a new disease developed in a small percentage of patients, so a high degree of suspicion is necessary to establish the diagnosis. Supportive care is of paramount importance. The use of Tocilizumab to control the inflammatory response is likely to be beneficial, but the best immunotherapeutic agent has not yet been established. Randomized clinical studies should be run to determine the best treatment. View Full-Text
Keywords: SARS-COV-2; PIMS-TS; MIS-C; Tocilizumab SARS-COV-2; PIMS-TS; MIS-C; Tocilizumab
Show Figures

Figure 1

MDPI and ACS Style

Niño-Taravilla, C.; Espinosa-Vielma, Y.P.; Otaola-Arca, H.; Poli-Harlowe, C.; Tapia, L.I.; Ortiz-Fritz, P. Pediatric Inflammatory Multisystem Syndrome Temporally Associated with SARS-CoV-2 Treated with Tocilizumab. Pediatr. Rep. 2020, 12, 142-148. https://doi.org/10.3390/pediatric12030029

AMA Style

Niño-Taravilla C, Espinosa-Vielma YP, Otaola-Arca H, Poli-Harlowe C, Tapia LI, Ortiz-Fritz P. Pediatric Inflammatory Multisystem Syndrome Temporally Associated with SARS-CoV-2 Treated with Tocilizumab. Pediatric Reports. 2020; 12(3):142-148. https://doi.org/10.3390/pediatric12030029

Chicago/Turabian Style

Niño-Taravilla, Carmen, Yazmín P. Espinosa-Vielma, Hugo Otaola-Arca, Cecilia Poli-Harlowe, Lorena I. Tapia, and Paula Ortiz-Fritz. 2020. "Pediatric Inflammatory Multisystem Syndrome Temporally Associated with SARS-CoV-2 Treated with Tocilizumab" Pediatric Reports 12, no. 3: 142-148. https://doi.org/10.3390/pediatric12030029

Find Other Styles

Article Access Map by Country/Region

1
Back to TopTop